EUVIMEDEUVIMED entdecken
Crossref

Discovery and Evaluation of TLR-Targeted Immune Agonists

Natalia Chernyak iD, Bhagyashree Bhagwat, Saraswathi Naravula, Ying Chen, Nicolas Solban, Fan Zhang, Esther Kofman, Fahimeh Raoufi, Xibei Dang iD, Jianming Bao, Daniela Tomazela, Marc Baily und 5 weitere

Journal of Medicinal Chemistry · 26.09.2024 · 67 (18) · 16222-16234

DOI: 10.1021/acs.jmedchem.4c00804 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Medicinal Chemistry, online erschienen am 05.09.2024. Verfasst von Natalia Chernyak und 16 weiteren Autor:innen. Beteiligte Einrichtung: Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States. Hauptthemen laut MEDLINE: Toll-Like Receptor 7. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 54 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Toll-like receptor (TLR) activation converts immunologically inactive tumors into immunologically active tumors by activating tumor residing antigen-presenting cells and recruitment of cytotoxic T lymphocytes. Targeted immune agonists (TIAs) are antibody drug conjugates with small-molecule TLR agonist payloads. The mechanism of action of TIAs involves tumor antigen recognition, Fcγ-receptor-dependent phagocytosis, and TLR-mediated activation to drive tumor killing by myeloid cells. Several new low DAR anti-HER2 TIAs conjugated with novel TLR7 or dual-TLR7/8 agonists with cleavable and noncleavable linkers were synthesized and profiled. In vitro studies demonstrated that these TIAs activate myeloid cells only in the presence of antigen-expressing cancer cells. Evaluation in ELISpot-based assays confirmed the low immunogenicity of these constructs. Systemic administration of the novel TIAs in tumor-bearing mice resulted in tumor reduction at low doses. These results provide a strong rationale for further development of the TIAs as a novel class of immunotherapeutics.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Toll-Like Receptor 7AnimalsFemaleHumansMiceAntibodiesAntineoplastic AgentsCell Line, TumorDrug DiscoveryImmunoconjugatesErb-b2 Receptor Tyrosine KinasesToll-Like Receptor 8Toll-Like Receptors

Substanzen

AntibodiesAntineoplastic AgentsImmunoconjugatesErb-b2 Receptor Tyrosine KinasesToll-Like Receptor 7Toll-Like Receptor 8Toll-Like Receptors

Autor:innen und Institutionen

  • Discovery Chemistry, Merck & Co., Inc., South San Francisco, California 94080, United States.
  • Discovery Biologics, Merck & Co., Inc., South San Francisco, California 94080, United States.
  • Pharmacokinetics, Dynamics, Metabolism and Bioanalytics, Merck & Co., Inc., South San Francisco, California 94080, United States.
  • Quantitative Biosciences, Merck & Co., Inc., Boston, Massachusetts 02115, United States.
  • Discovery Oncology, Merck & Co., Inc., South San Francisco, California 94080, United States.

ORCID-Profile: Natalia Chernyak, Xibei Dang, W Michael Seganish

Zitieren

APA

Chernyak, N., Bhagwat, B., Naravula, S., Chen, Y., Solban, N., Zhang, F., Kofman, E., Raoufi, F., Dang, X., Bao, J., Tomazela, D., Baily, M., Geierstanger, B., Flygare, J. A., Han, J. H., Willingham, A., & Seganish, W. M. (2024). Discovery and Evaluation of TLR-Targeted Immune Agonists. Journal of Medicinal Chemistry, 67(18), 16222-16234. https://doi.org/10.1021/acs.jmedchem.4c00804

Vancouver

Chernyak N, Bhagwat B, Naravula S, Chen Y, Solban N, Zhang F, et al. Discovery and Evaluation of TLR-Targeted Immune Agonists. Journal of Medicinal Chemistry. 2024;67(18):16222-16234. doi:10.1021/acs.jmedchem.4c00804

BibTeX
@article{Chernyak2024,
  author = {Chernyak, Natalia and Bhagwat, Bhagyashree and Naravula, Saraswathi and Chen, Ying and Solban, Nicolas and Zhang, Fan and Kofman, Esther and Raoufi, Fahimeh and Dang, Xibei and Bao, Jianming and Tomazela, Daniela and Baily, Marc and Geierstanger, Bernhard and Flygare, John A and Han, Jin-Hwan and Willingham, Aarron and Seganish, W Michael},
  title = {Discovery and Evaluation of TLR-Targeted Immune Agonists},
  journal = {Journal of Medicinal Chemistry},
  year = {2024},
  volume = {67},
  number = {18},
  pages = {16222--16234},
  doi = {10.1021/acs.jmedchem.4c00804}
}
Kostenlos starten →